Article | January 18, 2022

Selecting Drug Delivery Systems For Higher Doses, Higher Viscosities, And Lower Risk

By: Nicolas Bralet and Megan Lan, MBA, MA


The development of new parenteral biologics with high-volume, high-viscosity formulations (&GT 1 mL, &GT15 cP) is triggering the need for devices that can deliver these therapies with the ease, safety, and low injection time required for self-injection.1-3 As these formulations come to market, pharmaceutical and biotech companies must make critical device choices from an array of largely unproven options.2 The following article discusses how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development

BD Medical - Pharmaceutical Systems